Nivolumab Versus Gemcitabine or Pegylated Liposomal Doxorubicin for Patients With Platinum-Resistant Ovarian Cancer: Open-Label, Randomized Trial in Japan (NINJA)

被引：119

作者：

Hamanishi, Junzo ^{[1
]}

Takeshima, Nobuhiro ^{[2
,3
]}

Katsumata, Noriyuki ^{[4
]}

Ushijima, Kimio ^{[5
]}

Kimura, Tadashi ^{[6
]}

Takeuchi, Satoshi ^{[7
,8
]}

Matsumoto, Koji ^{[9
]}

Ito, Kimihiko ^{[10
]}

Mandai, Masaki ^{[1
,11
]}

Nakai, Hidekatsu ^{[11
]}

Sakuragi, Noriaki ^{[12
,13
]}

Watari, Hidemichi ^{[12
]}

Takahashi, Nobutaka ^{[14
]}

Kato, Hidenori ^{[15
]}

Hasegawa, Kosei ^{[16
]}

Yonemori, Kan ^{[17
]}

Mizuno, Mika ^{[18
,19
]}

Takehara, Kazuhiro ^{[20
]}

Niikura, Hitoshi ^{[21
,22
]}

Sawasaki, Takashi ^{[23
,24
]}

Nakao, Sari ^{[25
]}

Saito, Toshiaki ^{[26
]}

Enomoto, Takayuki ^{[27
]}

Nagase, Satoru ^{[28
]}

Suzuki, Nao ^{[29
]}

Matsumoto, Takashi ^{[30
]}

Kondo, Eiji ^{[31
]}

Sonoda, Kenzo ^{[32
,33
]}

Aihara, Satomi ^{[34
,35
]}

Aoki, Yoichi ^{[36
]}

Okamoto, Aikou ^{[37
]}

Takano, Hirokuni ^{[38
]}

Kobayashi, Hiroshi ^{[39
,40
]}

Kato, Hisamori ^{[41
]}

Terai, Yoshito ^{[42
,43
]}

Takazawa, Akira ^{[44
]}

Takahashi, Yusuke ^{[45
]}

Namba, Yoshinobu ^{[46
]}

Aoki, Daisuke ^{[47
]}

Fujiwara, Keiichi ^{[16
]}

Sugiyama, Toru ^{[7
,48
]}

Konishi, Ikuo ^{[49
]}

机构：

[1] Kyoto Univ, Dept Gynecol & Obstet, Grad Sch Med, Kyoto, Japan

[2] JFCR, Dept Gynecol, Canc Inst Hosp, Tokyo, Japan

[3] Int Univ Hlth & Welf Hosp, Dept Obstet & Gynecol, Otawara, Japan

[4] Musashikosugi Hosp, Dept Med Oncol, Nippon Med Sch, Kawasaki, Kanagawa, Japan

[5] Kurume Univ, Dept Obstet & Gynecol, Sch Med, Kurume, Fukuoka, Japan

[6] Osaka Univ, Dept Obstet & Gynecol, Grad Sch Med, Suita, Osaka, Japan

[7] Iwate Med Univ Hosp, Dept Obstet & Gynecol, Morioka, Iwate, Japan

[8] Kobe Tokushukai Hosp, Dept Gynecol, Kobe, Hyogo, Japan

[9] Hyogo Canc Ctr, Dept Med Oncol, Akashi, Hyogo, Japan

[10] Kansai Rosai Hosp, Dept Obstet & Gynecol, Amagasaki, Hyogo, Japan

[11] Kindai Univ, Dept Obstet & Gynecol, Fac Med, Osakasayama, Japan

[12] Hokkaido Univ, Dept Obstet & Gynecol, Grad Sch Med, Sapporo, Hokkaido, Japan

[13] Otaru Gen Hosp, Dept Gynecol, Otaru, Hokkaido, Japan

[14] Shizuoka Canc Ctr, Div Gynecol, Shizuoka, Japan

[15] Hokkaido Canc Ctr, Dept Gynecol, Sapporo, Hokkaido, Japan

[16] Saitama Med Univ, Dept Gynecol Oncol, Int Med Ctr, Hidaka, Japan

[17] Natl Canc Ctr, Dept Breast & Med Oncol, Tokyo, Japan

[18] Aichi Canc Ctr Hosp, Dept Obstet & Gynecol, Nagoya, Aichi, Japan

[19] Kagoshima Univ Hosp, Dept Obstet & Gynecol, Kagoshima, Japan

[20] Natl Hosp Org Shikoku Canc Ctr, Dept Gynecol Oncol, Matsuyama, Ehime, Japan

[21] Tohoku Univ, Dept Obstet & Gynecol, Grad Sch Med, Sendai, Miyagi, Japan

[22] Natl Hosp Org Sendai Med Ctr, Dept Obstet & Gynecol, Sendai, Miyagi, Japan

[23] Natl Hosp Org Kure Med Ctr, Dept Obstet & Gynecol, Kure, Japan

[24] SAWASAKI Obstet Gynecol Clin, Kure, Japan

[25] Univ Tsukuba Hosp, Fac Med, Dept Obstet & Gynecol, Tsukuba, Ibaraki, Japan

[26] Natl Hosp Org Kyushu Canc Ctr, Gynecol Serv, Fukuoka, Fukuoka, Japan

[27] Niigata Univ, Dept Obstet & Gynecol, Grad Sch Med & Dent Sci, Niigata, Japan

[28] Yamagata Univ Hosp, Dept Obstet & Gynecol, Yamagata, Japan

[29] St Marianna Univ, Dept Obstet & Gynecol, Sch Med, Kawasaki, Kanagawa, Japan

[30] Ehime Univ Hosp, Dept Obstet & Gynecol, Toon, Japan

[31] Mie Univ Hosp, Dept Obstet & Gynecol, Tsu, Mie, Japan

[32] Kyushu Univ Hosp, Dept Obstet & Gynecol, Fukuoka, Fukuoka, Japan

[33] Natl Hosp Org Kyushu Canc Ctr, Dept Gynecol Oncol, Fukuoka, Fukuoka, Japan

[34] Saga Univ Hosp, Fac Med, Dept Obstet & Gynecol, Saga, Japan

[35] Eguchi Hosp, Dept Med Oncol, Saga, Japan

[36] Univ Ryukyus Hosp, Dept Obstet & Gynecol, Nishihara, Okinawa, Japan

[37] Jikei Univ Hosp, Dept Obstet & Gynecol, Tokyo, Japan

[38] Jikei Univ, Dept Obstet & Gynecol, Kashiwa Hosp, Kashiwa, Chiba, Japan

[39] Nara Med Univ Hosp, Dept Obstet & Gynecol, Kashihara, Nara, Japan

[40] Ms Clin MayOne, Kashihara, Nara, Japan

[41] Kanagawa Canc Ctr, Dept Gynecol, Yokohama, Kanagawa, Japan

[42] Osaka Med Coll Hosp, Dept Gynecol Oncol, Takatsuki, Osaka, Japan

[43] Kobe Univ, Obstet & Gynecol, Grad Sch Med, Kobe, Hyogo, Japan

[44] Ono Pharmaceut Co Ltd, Data Sci, Osaka, Japan

[45] Ono Pharmaceut Co Ltd, Oncol Clin Dev Unit, Osaka, Japan

[46] Ono Pharmaceut Co Ltd, Clin Sci, Osaka, Japan

[47] Keio Univ, Dept Obstet & Gynecol, Sch Med, Tokyo, Japan

[48] St Marys Hosp, Dept Obstet & Gynecol, Kurume, Fukuoka, Japan

[49] Natl Hosp Org Kyoto Med Ctr, Kyoto, Japan

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 33期

关键词：

PHASE-III TRIAL; ANTI-PD-1; ANTIBODY; ANTITUMOR-ACTIVITY; CHEMOTHERAPY; SAFETY; AVELUMAB; CELLS;

D O I：

10.1200/JCO.21.00334

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

PURPOSE This phase III, multicenter, randomized, open-label study investigated the efficacy and safety of nivolumab versus chemotherapy (gemcitabine [GEM] or pegylated liposomal doxorubicin [PLD]) in patients with platinum-resistant ovarian cancer. MATERIALS AND METHODS Eligible patients had platinum-resistant epithelial ovarian cancer, received <= 1 regimen after diagnosis of resistance, and had an Eastern Cooperative Oncology Group performance score of <= 1. Patients were randomly assigned 1:1 to nivolumab (240 mg once every 2 weeks [as one cycle]) or chemotherapy (GEM 1000 mg/m(2) for 30 minutes [once on days 1, 8, and 15] followed by a week's rest [as one cycle], or PLD 50 mg/m(2) once every 4 weeks [as one cycle]). The primary outcome was overall survival (OS). Secondary outcomes included progression-free survival (PFS), overall response rate, duration of response, and safety. RESULTS Patients (n = 316) were randomly assigned to nivolumab (n = 157) or GEM or PLD (n = 159) between October 2015 and December 2017. Median OS was 10.1 (95% CI, 8.3 to 14.1) and 12.1 (95% CI, 9.3 to 15.3) months with nivolumab and GEM or PLD, respectively (hazard ratio, 1.0; 95% CI, 0.8 to 1.3; P = .808). Median PFS was 2.0 (95% CI, 1.9 to 2.2) and 3.8 (95% CI, 3.6 to 4.2) months with nivolumab and GEM or PLD, respectively (hazard ratio, 1.5; 95% CI, 1.2 to 1.9; P = .002). There was no statistical difference in overall response rate between groups (7.6% v 13.2%; odds ratio, 0.6; 95% CI, 0.2 to 1.3; P = .191). Median duration of response was numerically longer with nivolumab than GEM or PLD (18.7 v 7.4 months). Fewer treatment-related adverse events were observed with nivolumab versus GEM or PLD (61.5% v 98.1%), with no additional or new safety risks. CONCLUSION Although well-tolerated, nivolumab did not improve OS and showed worse PFS compared with GEM or PLD in patients with platinum-resistant ovarian cancer. (C) 2021 by American Society of Clinical Oncology

引用

页码：3671 / +

页数：16

共 37 条

[1] Agresti A., 2012, CATEGORICAL DATA ANA
[2] [Anonymous], 1997, Survival Analysis: Techniques for Censored and Truncated Data
[3] [Anonymous], 2019, 44 C EUROPEAN SOC FO
[4] Reliability and validity of the functional assessment of cancer therapy-ovarian
Basen-Engquist, K
Bodurka-Bevers, D
Fitzgerad, MA
Webster, K
Cella, D
Hu, SH
Gershenson, DM
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (06) : 1809 - 1817
[5] The use of confidence or fiducial limits illustrated in the case of the binomial.
Clopper, CJ
Pearson, ES
[J]. BIOMETRIKA, 1934, 26 : 404 - 413
[6] Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy
Cristescu, Razvan
Mogg, Robin
Ayers, Mark
Albright, Andrew
Murphy, Erin
Yearley, Jennifer
Sher, Xinwei
Liu, Xiao Qiao
Lu, Hongchao
Nebozhyn, Michael
Zhang, Chunsheng
Lunceford, Jared
Joe, Andrew
Cheng, Jonathan
Webber, Andrea L.
Ibrahim, Nageatte
Plimack, Elizabeth R.
Ott, Patrick A.
Seiwert, Tanguy
Ribas, Antoni
McClanahan, Terrill K.
Tomassini, Joanne E.
Loboda, Andrey
Kaufman, David
[J]. SCIENCE, 2018, 362 (6411) : 197 - +
[7] Turning Cold into Hot: Firing up the Tumor Microenvironment
Duan, Qianqian
Zhang, Hualing
Zheng, Junnian
Zhang, Lianjun
[J]. TRENDS IN CANCER, 2020, 6 (07): : 605 - 618
[8] Hamanishi J, 2018, INT J GYNAECOL OBSTE, V143, P43
[9] Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer
Hamanishi, Junzo
Mandai, Masaki
Iwasaki, Masashi
Okazaki, Taku
Tanaka, Yoshimasa
Yamaguchi, Ken
Higuchi, Toshihiro
Yagi, Haruhiko
Takakura, Kenji
Minato, Nagahiro
Honjo, Tasuku
Fujii, Shingo
[J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2007, 104 (09) : 3360 - 3365
[10] Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer
Hamanishi, Junzo
Mandai, Masaki
Ikeda, Takafumi
Minami, Manabu
Kawaguchi, Atsushi
Murayama, Toshinori
Kanai, Masashi
Mori, Yukiko
Matsumoto, Shigemi
Chikuma, Shunsuke
Matsumura, Noriomi
Abiko, Kaoru
Baba, Tsukasa
Yamaguchi, Ken
Ueda, Akihiko
Hosoe, Yuko
Morita, Satoshi
Yokode, Masayuki
Shimizu, Akira
Honjo, Tasuku
Konishi, Ikuo
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (34) : 4015 - +

← 1 2 3 4 →